View in EDS HTML Full Text PDF Full Text

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.

Saved in:
Bibliographic Details
Title: Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
Authors: Chanchlani, Neil1,2 (AUTHOR), Lin, Simeng1,2 (AUTHOR), Chee, Desmond1,2 (AUTHOR), Hamilton, Benjamin1,2 (AUTHOR), Nice, Rachel3 (AUTHOR), Arkir, Zehra4 (AUTHOR), Bewshea, Claire2 (AUTHOR), Cipriano, Bessie5 (AUTHOR), Derikx, Lauranne A A P6,7 (AUTHOR), Dunlop, Allan8 (AUTHOR), Greathead, Louise9 (AUTHOR), Griffiths, Rachel L10 (AUTHOR), Ibraheim, Hajir11,12 (AUTHOR), Kelleher, Peter9,13 (AUTHOR), Kok, Klaartje B5,14 (AUTHOR), Lees, Charlie W6,15 (AUTHOR), MacDonald, Jonathan16,17 (AUTHOR), Sebastian, Shaji18,19 (AUTHOR), Smith, Philip J20 (AUTHOR), McDonald, Timothy J3 (AUTHOR)
Source: Journal of Crohn's & Colitis. Mar2022, Vol. 16 Issue 3, p389-397. 9p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:18739946
DOI:10.1093/ecco-jcc/jjab153